Helsinn Group and Angelini Ink an Agreement for License Rights to Phase-III Ghrelin Receptor Agonist Anamorelin in Central & Eastern Europe
Swiss Pharma Group Helsinn grants exclusive distribution and licensing rights to Angelini, through its subsidiary company CSC Pharmaceuticals, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary, Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS countries of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC).
